Victoria Sarne

Ms. Victoria Sarne

Medical University of Vienna, Austria
orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2017 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
ECEmarndeena H Cheteh
Emarndeena H Cheteh
MAMartin Augsten
Martin Augsten
HRHelene Rundqvist
Helene Rundqvist
JBJulie Bianchi
Julie Bianchi
VSVictoria Sarne
Victoria Sarne
KWKlas G Wiman
Klas G Wiman
Drug resistance is a major problem in cancer therapy. A growing body of evidence demonstrates that the tumor microenvironment, including cancer-associated fibroblasts (CAFs), can modulate drug sensitivity in tumor cells. We examined the effect of primary human CAFs on p53 induction and cell viability in prostate cancer cells on treatment with chemotherapeutic drugs. Co-culture with prostate CAFs or CAF-conditioned medium attenuated DNA damage and the p53 response to chemotherapeutic drugs and enhanced prostate cancer cell survival. CAF-conditioned medium inhibited the accumulation of doxorubicin, but not taxol, in prostate cancer cells in a manner that was associated with increased cancer cell glutathione levels. A low molecular weight fraction (<3 kDa) of CAF-conditioned medium had the same effect. CAF-conditioned medium also inhibited induction of reactive oxygen species (ROS) in both doxorubicin- and taxol-treated cancer cells. Our findings suggest that CAFs can enhance drug resistance in cancer cells by inhibiting drug accumulation and counteracting drug-induced oxidative stress. This protective mechanism may represent a novel therapeutic target in cancer.

2 June 2020 in Cell Death Discovery
Verified
Journal Article
Open access
PDF file
ECEmarndeena H. Cheteh
Emarndeena H. Cheteh
VSVictoria Sarne
Victoria Sarne
SCSophia Ceder
Sophia Ceder
JBJulie Bianchi
Julie Bianchi
MAMartin Augsten
Martin Augsten
KWKlas G. Wiman
Klas G. Wiman
Cancer-associated fibroblasts (CAFs) promote tumor growth and progression, and increase drug resistance through several mechanisms. We have investigated the effect of CAFs on the p53 response to doxorubicin in prostate cancer cells. We show that CAFs produce interleukin-6 (IL-6), and that IL-6 attenuates p53 induction and upregulation of the pro-apoptotic p53 target Bax upon treatment with doxorubicin. This is associated with increased levels of MDM2 mRNA, Mdm2 protein bound to p53, and ubiquitinated p53. IL-6 also inhibited doxorubicin-induced cell death. Inhibition of JAK or STAT3 alleviated this effect, indicating that IL-6 attenuates p53 via the JAK/STAT signaling pathway. These results suggest that CAF-derived IL-6 plays an important role in protecting cancer cells from chemotherapy and that inhibition of IL-6 could have significant therapeutic value.

30 January 2021 in Molecules
Verified
Journal Article
Open access
PDF file
HHHarald Hundsberger
Harald Hundsberger
ASAnna Stierschneider
Anna Stierschneider
VSVictoria Sarne
Victoria Sarne
DRDoris Ripper
Doris Ripper
JSJasmin Schimon
Jasmin Schimon
Christoph WiesnerChristoph Wiesner
Christoph Wiesner
Quercetin, a dietary flavonoid found in fruits and vegetables, has been described as a substance with many anti-cancer properties in a variety of preclinical investigations. In the present study, we demonstrate that 2D and 3D melanoma models exhibit not only different sensitivities to quercetin, but also opposite, cancer-promoting effects when metastatic melanoma spheroids are treated with quercetin. Higher concentrations of quercetin reduce melanoma growth in three tested cell lines, whereas low concentrations induce the opposite effect in metastatic melanoma spheroids but not in the non-metastatic cell line. High (>12.5 µM) or low (0.4 µM), whereas in 3D spheroids apoptotic cells, caspase 3 activity can only be detected in concentrations ≥12.5 µM. Further, we show that the tumor promoting or repressing effect in the 3D metastatic melanoma spheroids are likely to be elicited by a precisely controlled regulation of Nrf2/ARE-mediated cytoprotective genes, as well as ERK and NF-κB phosphorylation. According to the results obtained here, further studies are needed to better characterize the mechanisms of action underlying the pro- and anti-carcinogenic effects of quercetin on human melanomas.

Verified
Journal Article
Open access
PDF file
VSVictoria Sarne
Victoria Sarne
SHSamuel Huter
Samuel Huter
SBSandrina Braunmueller
Sandrina Braunmueller
LRLisa Rakob
Lisa Rakob
NJNico Jacobi
Nico Jacobi
Rita SeeböckRita Seeböck
Rita Seeböck
Specific gene promoter DNA methylation is becoming a powerful epigenetic biomarker in cancer diagnostics. Five genes (CDH1, CDKN2Ap16, RASSF1A, TERT, and WT1) were selected based on their frequently published potential as epigenetic markers. Diagnostic promoter methylation assays were generated based on bisulfite-converted DNA pyrosequencing. The methylation patterns of 144 non-small-cell lung cancer (NSCLC) and 7 healthy control formalin-fixed paraffin-embedded (FFPE) samples were analyzed to evaluate the applicability of the putative diagnostic markers. Statistically significant changes in methylation levels are shown for TERT and WT1. Furthermore, 12 NSCLC and two benign lung cell lines were characterized for promoter methylation. The in vitro tests involved a comparison of promoter methylation in 2D and 3D cultures, as well as therapeutic tests investigating the impact of CDH1/CDKN2Ap16/RASSF1A/TERT/WT1 promoter methylation on sensitivity to tyrosine kinase inhibitor (TKI) and DNA methyl-transferase inhibitor (DNMTI) treatments. We conclude that the selected markers have potential and putative impacts as diagnostic or even predictive marker genes, although a closer examination of the resulting protein expression and pathway regulation is needed.

20 April 2022 in International Journal of Biological Macromolecules
Verified
Journal Article
Closed access
Hannes SteinkellnerHannes Steinkellner
Hannes Steinkellner
PKPrakasha Kempaiah
Prakasha Kempaiah
ABAlexander V. Beribisky
Alexander V. Beribisky
SPSandra Pferschy
Sandra Pferschy
JEJulia Etzler
Julia Etzler
FLFranco Laccone
Franco Laccone

12 May 2022 in The Protein Journal
Verified
Journal Article
Open access
PDF file
ABAlexander Beribisky
Alexander Beribisky
HSHannes Steinkellner
Hannes Steinkellner
SGSofia Geislberger
Sofia Geislberger
AHAnna Huber
Anna Huber
VSVictoria Sarne
Victoria Sarne
FLFranco Laccone
Franco Laccone
The transcriptional regulator Methyl-CpG-binding protein 2 (MeCP2) is an intrinsically disordered protein, mutations in which, are implicated in the onset of Rett Syndrome, a severe and debilitating neurodevelopmental disorder. Delivery of this protein fused to the cell-penetrating peptide TAT could allow for the intracellular replenishment of functional MeCP2 and hence potentially serve as a prospective Rett Syndrome therapy. This work outlines the expression, purification and characterization of various TAT-MeCP2 constructs as well as their full-length and shortened eGFP fusion variants. The latter two constructs were used for intracellular uptake studies with subsequent analysis via western blotting and live-cell imaging. All purified MeCP2 samples exhibited high degree of stability and very little aggregation propensity. Full length and minimal TAT-MeCP2-eGFP were found to efficiently transduce into human dermal and murine fibroblasts and localize to cell nuclei. These findings clearly support the utility of MeCP2-based protein replacement therapy as a potential Rett Syndrome treatment option.